Heterologous Transplantation of Mammalian Tumors

Greene, Harry S. N.

doi:10.1084/jem.73.4.461

Cited by 119 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Green et al [60] observed that H-31 rabbit carcinoma tumor implanted into the eyes of guinea pigs did not vascularize and failed to grow for 16-26 months. The transplants remained at a size of approximately 2.5 mm in diameter for the duration of the experiment.…”

Section: Experimental Models Of Human Tumor Dormancymentioning

confidence: 99%

Tumor dormancy due to failure of angiogenesis: role of the microenvironment

Naumov

Folkman

Straume

2008

Clin Exp Metastasis

109

View full text Add to dashboard Cite

Tumor progression is dependent on a number of sequential steps, including initial recruitment of blood vessels (i.e., angiogenic switch). Failure of a microscopic tumor to complete one or more of these early steps may lead to delayed clinical manifestation of the cancer. In this review we summarize some of the clinical and experimental evidence suggesting that microscopic human cancers can remain in an asymptomatic, non-detectable, and occult state for the life of a person or animal. We present three clinical cases where tumors present shortly after an accidental trauma in otherwise healthy individuals. We also review current experimental human tumor dormancy models with special emphasis on the angiogenic switch which closely recapitulates clinically observed delay in tumor recurrence.

show abstract

Section: Experimental Models Of Human Tumor Dormancymentioning

confidence: 99%

Tumor dormancy due to failure of angiogenesis: role of the microenvironment

Naumov

Folkman

Straume

2008

Clin Exp Metastasis

109

View full text Add to dashboard Cite

show abstract

“…For solid tumors to proliferate beyond a certain size, tumor blood vessels are indispensable (1)(2)(3). Many studies on vessel formation and morphology have been reported, and will not be reviewed here.…”

Section: Introductionmentioning

confidence: 99%

Functional characterization of the microcirculation in tumors

et al. 1984

View full text Add to dashboard Cite

This review describes some aspects of tumor vessels and the influence of vasoactive agents on tumor blood flow, particularly the characteristic microcirculation of tumors with regard to its selective increase in blood flow. Elevation of blood pressure by infusion of angiotensin II produced a severalfold increase in tumor blood flow. The increase was selective and specific to the tumor vessels as long as the mean arterial blood pressure was kept under 150 mm Hg. Pressure elevation by angiotensin II also selectively increased tumor oxygen tension and influx of lymph flow from the primary transplanted lesion to the lymph node metastatic lesion. Newly devised techniques for analyzing microhemodynamics of tumor vessels showed that the velocity of tumor blood flow, the vascular area in tumor tissue, and the hydrostatic pressure difference between the tumor vessel and extravascular tissue were markedly enhanced. Thus, the extravasation of material into tumor tissues can be increased by the enhancement of blood flow. This demonstration allowed the development of a new approach to cancer chemotherapy, in which the delivery to tumor tissue of systemically administered anticancer drugs can be selectively enhanced.

show abstract

“…Folkman and others first showed that, in the absence of vascularization, tumor growth arrested when the tumor reached 2–3 mm in diameter, presumably owing to limited diffusion of oxygen, nutrients, and waste products. Furthermore, small, dormant tumors would quickly resume expansion when allowed to initiate neovascularization 3–5…”

Section: Angiogenesis Tumor Growth and Antiangiogenesismentioning

confidence: 99%

From antiangiogenesis to hypoxia: current research and future directions

Rice¹,

Huang²

2010

CMR

View full text Add to dashboard Cite

Angiogenesis has long been recognized as an essential element in tumor growth. Since the conception of antiangiogenesis for cancer therapeutics, great strides have been made in understanding the molecular biology underlying angiogenesis, both in cancer and in physiology. By capitalizing on these advancements through bench-to-bedside research, potent antiangiogenic agents have been developed and tested. To date, the clinical results of most of these antiangiogenic agents have not met expectations. Even with the most successful agents, such as bevacizumab, used either as single agents or in combination with chemotherapy, gains in overall survival of cancer patients have been modest in most cases. In this article, the authors present the evolving views of antiangiogenic therapy, review recent experimental and clinical studies on antiangiogenesis, and address the fundamental role of hypoxia in tumor progression, which may be key to improving the efficacy of antiangiogenic therapy.

show abstract

Heterologous Transplantation of Mammalian Tumors

Cited by 119 publications

References 8 publications

Tumor dormancy due to failure of angiogenesis: role of the microenvironment

Tumor dormancy due to failure of angiogenesis: role of the microenvironment

Functional characterization of the microcirculation in tumors

From antiangiogenesis to hypoxia: current research and future directions

Contact Info

Product

Resources

About